Table 2

Photofrin uptake in intraperitoneal malignancies

Patient no.HistologyCohortSpecimenPhotofrin uptake (ng/mg)aInterspecimen median (range)bInterspecimen mean (SE)c
1GISTdSarcoma11.261.261.3 (1.1)
2GISTSarcoma1, 2, and 33.28, 1.34, and 0.961.34 (2.32)1.9 (0.6)
3Ovarian CAOvarian1, 2, and 31.99, 3.14, and 2.912.91 (1.15)2.7 (0.6)
4Ovarian CAOvarian1, 2, 3, and 44.44, 5.26, 4.30, and 1.724.37 (3.54)3.9 (0.5)
5Colon CAGI1, 2, and 34.63, 2.79, and 4.124.12 (1.84)3.9 (0.5)
4 and 53.32 and 4.49
6Colon CAGI1, 2, and 33.06, 4.44, and 3.503.84 (1.68)3.9 (0.4)
4, 5, 6, and 74.74, 3.32, 3.84, and 4.36
7Colon CAGI1, 2, and 30.66, 0.39, and 0.870.77 (3.89)1.2 (0.4)
4, 5, 6, and 70.91, 0.38, 0.77, and 4.27
8Small bowel CAGI1, 2, and 35.30, 4.79, and 6.405.80 (1.88)5.8 (0.5)
4 and 56.67 and 5.80
9Appendiceal CAGI1 and 20.98 and 0.130.55 (0.85)0.6 (0.8)
10Appendiceal CAGI1, 2, and 30.68, 0.78, and 0.680.78 (3.52)1.3 (0.4)
4, 5, and 63.91, 1.36, and 0.39
  • a Drug uptake was measured by fluorescence in whole tumor nodules after tissue solubilization.

  • b Median and range (largest-smallest) of values of specimens for each patient.

  • c The model-based mean (SE) of specimens for each patient.

  • d GIST, gastrointestinal stromal tumor; CA, carcinoma; GI, gastrointestinal.